Clobazam Oral Suspension (Zacco) Now Registered in Bahrain
The availability of Clobazam Oral Suspension (Zacco) has now been officially registered in Bahrain, strengthening access to reliable neurological and psychiatric treatment options across the region.
This registration marks a key advancement in ensuring that patients and healthcare professionals in Bahrain can access a high-quality, sugar-free, and alcohol-free formulation of Clobazam, developed to improve dosing flexibility and patient compliance. Through its established expertise in regulatory and distribution support, Pharma Solutions continues to help global pharmaceutical brands like Zacco expand their presence across the MENA and GCC regions, making critical therapies more accessible to those who need them most.
About Clobazam (Zacco) Oral Suspension
Clobazam (Zacco) belongs to the benzodiazepine class of medicines, recognized for its anticonvulsant and anxiolytic properties. It enhances the action of the neurotransmitter GABA (gamma-aminobutyric acid), which helps calm the nervous system and control excessive brain activity.
The product is indicated for:
- Short-term treatment of severe anxiety in adults
- Adjunctive therapy in epilepsy for adults and children aged 2 years and above
Zacco Oral Suspension offers a patient-friendly alternative to conventional tablets, making it especially suitable for paediatric, elderly, or dysphagic patients who require flexible dosing.
Key Product Highlights
- Available Strengths: 5 mg/5 ml and 10 mg/5 ml
- Formulation: Sugar-free and alcohol-free oral suspension
- Ease of Use: Supplied with a 5 ml oral syringe and adaptor for accurate dosing
- Quality Manufacturing: Produced under strict European GMP standards by Delpharm Bladel B.V., Netherlands
- Marketing Authorisation Holder: Thame Laboratories, United Kingdom
- Brand Name: Zacco
Each bottle is securely packaged with a child-resistant cap and dosing device, ensuring precision and safety with every administration.
Enhancing Access in Bahrain and Beyond
The registration of Clobazam (Zacco) in Bahrain represents an important step toward expanding access to neurology and psychiatry treatments in the region. With Pharma Solutions’ support, healthcare providers across Bahrain can now source and prescribe a trusted formulation that meets international quality benchmarks.
Pharma Solutions acts as a strategic partner for pharmaceutical brands, such as Zacco, facilitating product registration, regulatory compliance, market access, and distribution across the Middle East and North Africa. This collaboration ensures that patients in Bahrain and neighbouring markets benefit from safe, effective, and well-regulated medicines.
Partner with Pharma Solutions
Pharma Solutions continues to work alongside leading global manufacturers to bridge the gap between innovation and accessibility. To know more about Clobazam (Zacco) Oral Suspension, or to explore partnership opportunities for product registration and distribution across MENA and GCC, visit
www.pharmasolutions-int.com today.
Enquire now to collaborate in bringing advanced therapies closer to healthcare providers and patients across the region.
